Al­ler­gan vet In­gram takes the helm at Sarep­ta; Big Phar­ma alum­ni Cather­ine Steele is the new comms chief at Bio­gen

Ed Kaye will now be tran­si­tion­ing out of Sarep­ta, as planned. The board an­nounced this week that Doug In­gram will be tak­ing over the Duchenne mus­cu­lar dy­s­tro­phy com­pa­ny. In­gram is the for­mer pres­i­dent of Al­ler­gan, step­ping out af­ter the big merg­er with Ac­tavis. He then went to run Chase, and sold the Alzheimer’s com­pa­ny to Al­ler­gan. Now he’ll be in charge of ex­pand­ing sales for Sarep­ta’s Ex­ondys 51 and run­ning the pipeline as an­a­lysts spec­u­late whether an­oth­er M&A deal could be in the works.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.